Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in Advanced/Metastatic Cholangiocarcinoma with FGFR2 Fusion or Rearrangement
NCT07862998Phase 2Not yet recruiting
- Sponsor
- Incyte
- Start
- Dec 2026
- Primary completion
- Feb 2031
01
Overview
A Phase 2 trial of pemigatinib in cholangiocarcinoma (CCA), sponsored by Incyte. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
pemigatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT07862998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07862998.